Dipyrone use during pregnancy and adverse perinatal events

  • Tatiane da Silva Dal Pizzol
  • Lavínia Schüler-Faccini
  • Sotero Serrate Mengue
  • Maria Isabel Fischer
Original Article

Abstract

Objective

To evaluate the risk of adverse perinatal events among newborns exposed to dipyrone during gestation.

Design and Setting

The present study is a secondary analysis of Brazilian study of gestational diabetes (EBDG), a cohort of women attended at healthcare units of the Brazilian national health system (SUS) located in six Brazilian state capitals, between February 1991 and June 1995.

Sample

A total number of 5,564 women aged 20 years and over who were between their 21st and 28th week of pregnancy were followed up.

Methods

A structured questionnaire was used to obtain data on the pregnant women, their pregnancies, and their use of medications. Other data and the outcomes congenital abnormalities, intrauterine death, preterm birth, or low birth weight were obtained from the medical records. To estimate the odds ratios after adjustment for the potential confounding factors, logistic regression modeling was developed.

Main outcome measures

Congenital abnormalities, intrauterine death, preterm birth, and low birth weight.

Results

Dipyrone use was reported by 555 pregnant women (11.5%). Their exposure to this medication did not present any association with the outcomes of congenital abnormalities (OR 1.11; 95% CI, 0.58–2.10), intrauterine death (OR 0.69; 95% CI, 0.33–1.43), preterm birth (OR 0.94; 95% CI, 0.73–1.20), or low birth weight (OR 0.88; 95% CI, 0.64–1.22), in the crude analysis. This absence of associations was maintained after performing logistic regression analysis.

Conclusions

The data suggest that the exposure to dipyrone during pregnancy does not increase the risk of congenital abnormalities and other adverse events as outcomes from pregnancy.

Keywords

Dipyrone Congenital abnormalities Intrauterine death Preterm birth Low birth weight 

References

  1. 1.
    The international agranulocytosis aplastic anemia study (1986) Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 256:1749–1757. doi:10.1001/jama.256.13.1749 CrossRefGoogle Scholar
  2. 2.
    Andersohn F, Konzen C, Garbe E (2007) Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146:657–665PubMedGoogle Scholar
  3. 3.
    International panel on the evaluation of safety of dipyrone use (on line) (2007). Available on 20 April 2007 at http://www.anvisa.gov.br/divulga/informes/relatoriodipirona2.pdf
  4. 4.
    Mengue SS, Shenkel EP, Duncan BB, Schmidt MI (2001) Drug use by pregnant women in six Brazilian cities. Rev Saude Publica 35:415–420. doi:10.1590/S0034-89102001000500002 PubMedCrossRefGoogle Scholar
  5. 5.
    Fonseca MR, Fonseca E, Bergsten-Mendes G (2002) Prevalence of drug use during pregnancy: a pharmacoepidemiology approach. Rev Saude Publica 36:205–212PubMedGoogle Scholar
  6. 6.
    Sharpe CR, Franco EL (1996) Use of dipyrone during pregnancy and risk of Wilm’s tumor. Epidemiology 7:533–535. doi:10.1097/00001648-199609000-00014 PubMedCrossRefGoogle Scholar
  7. 7.
    Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera ME, Chan Li C et al (2001) Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 61:2542–2546PubMedGoogle Scholar
  8. 8.
    Catalán JL, Santonja J, Martinez L, Jiménez NV (1994) Oligoamnios asociado al uso de dipirona. Med Clin (Barc) 105:541–543Google Scholar
  9. 9.
    Sánchez de la Nieta MD, Rivera F, de la Torre M, Alcázar R, Caparrós G, Paz Alcaide M et al (2003) Acute renal failure and oligohydramnios induced by magnesium dipyrone (metamizol) in a pregnant women. Nephrol Dial Transplant 18:1679–1680. doi:10.1093/ndt/gfg240 PubMedCrossRefGoogle Scholar
  10. 10.
    Weintraub A, Mankuta D (2006) Dipyrone-induced oligohydramnios and ductus arteriosus restriction. Isr Med Assoc J 8:722–723PubMedGoogle Scholar
  11. 11.
    Martí Solé JJ, Pasarisas Sala M (1996) Possible association between the administration of metamizol to mothers and persistent pulmonary hypertension in neonates. An Esp Pediatr 44:387–388PubMedGoogle Scholar
  12. 12.
    Bar-Oz B, Clementi M, di Giantonio E (2005) Metamizol (dipyrone, optalgin) in pregnancy, is it safe? A prospective comparative study. Eur J Obstet Gynecol Reprod Biol 119:176–179. doi:10.1016/j.ejogrb.2004.07.004 PubMedCrossRefGoogle Scholar
  13. 13.
    Bánhidy F, Ács N, Puhó E, Czeizel AE (2007) A population-based case-control teratologic study of oral dipyrone treatment during pregnancy. Drug Saf 30:59–70. doi:10.2165/00002018-200730010-00006 PubMedCrossRefGoogle Scholar
  14. 14.
    Brazil. Ministry of Health. Secretary of ScienceTechnology Strategic Products. Department of Pharmaceutical Assistance Strategic Products (2007) National list of essential medicines—RENAME, 4th edn. Ministry of Health Press, Brasília, p 285Google Scholar
  15. 15.
    Izumi K, Sano N, Otsuka H, Kinouchi T, Ohnishi Y (1991) Tumor promoting potential in male F344 rats and mutagenicity in Salmonella typhimurium of dipyrone. Carcinogenesis 12:1221–1225. doi:10.1093/carcin/12.7.1221 PubMedCrossRefGoogle Scholar
  16. 16.
    Giri AK, Mukhopadhyay A (1998) Mutagenicity assay in Salmonella and in vivo sister chromatid exchange in bone marrow cells of mice for four pyrazolone derivatives. Mutat Res 420:15–25PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Tatiane da Silva Dal Pizzol
    • 1
  • Lavínia Schüler-Faccini
    • 2
  • Sotero Serrate Mengue
    • 3
  • Maria Isabel Fischer
    • 4
  1. 1.Departamento de Produção e Controle de Medicamentos, Faculdade de FarmáciaUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  2. 2.Departamento de GenéticaUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  3. 3.Programa de Pós-Graduação em Epidemiologia, Faculdade de MedicinaUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  4. 4.Centro de Informações sobre Medicamentos, Conselho Regional de Farmácia do Rio Grande do Sul e Faculdade de FarmáciaUniversidade Federal do Rio Grande do SulPorto AlegreBrazil

Personalised recommendations